Objectives. Opiate analgesics are the most effective treatments for severe pain, but their clinical utility is often hampered by the development of analgesic tolerance. There are striking similarities between morphine actions and neuropathic pain. We have demonstrated that B vitamins can attenuate neuropathic pain after peripheral nerve injury, sensory neuron inflammation/compression, and transient spinal cord ischemia. Given this similarity, the present study investigated whether B vitamins might be able to modify the antinociceptive effect of morphine as well as morphine tolerance in mice.
Methods. Cell signaling was assayed by Western blot and immunohistochemistry. Antinociception was assessed in ICR mice using the tail flick. The effects of B vitamins on acute morphine-induced antinociception and chronic morphine tolerance were studied.
Results. 1) Co-administration of B vitamins with morphine potentiates acute morphine antinociception. 2) B vitamins attenuate the development of antinociceptive tolerance to chronic morphine administration and inhibit morphine-induced p-NR1, p-PKC in the spinal cord. 3) Morphine induces microglial activation, as evidenced by increased p38 MAPK phosphorylation, IBA1, and IL-1b in the spinal cord, and these changes are inhibited by B vitamins. 4) Treatment of B vitamins alone shows no notable effects on pain threshold and activity of microglia in vivo.
Introduction
Opioids such as morphine are the most effective means of managing severe pain [1, 2] . Unfortunately, the undesirable side effects such as antinociceptive tolerance resulting from repeated opioid administration limit the therapeutic effects [1] .
Many investigators have attempted to elucidate the mechanisms underlying the development of morphine analgesic tolerance, and some aspects of molecular and cellular mechanisms are now revealed [3] [4] [5] [6] [7] [8] [9] . The NMDA receptor activation-dependent glutamatergic system is one of the most prominent candidates for an anti-opioid system in the development of neuronal plasticity [6, [10] [11] [12] , because a variety of NMDA receptor antagonists were found to suppress the development of morphine tolerance [10, 12, 13] .
It also has indicated that morphine exposure induces activation of spinal microglia [14, 15] , which secrete numerous pro-inflammatory cytokines, such as interleukin (IL)-6, tumor necrosis factor (TNF)-a, and IL-1b, accelerating the development of morphine tolerance [14, 16] . Intrathecal (i.t.) injection of a microglial inhibitor, minocycline, can significantly reduce tolerance with chronic opioid administration [14, 17] and neuropathic pain syndromes in animals with peripheral nerve injury [18] . However, minocycline has severe side effects, including diphtheritic enteritis and autoimmune disorders, which significantly hinder its prolonged use [19] . Therefore, a safe and potent drug is urgently needed for the prevention of morphine tolerance that develops through NMDA receptor and/or microglia inhibition.
The B vitamins, especially thiamine (B1), pyridoxine (B6), and cyanocobalamin (B12), have been demonstrated to be clinically useful in treating some chronic painful disorders such as neuropathic pain [20, 21] , trigeminal neuralgia [22] , diabetic neuropathy [23, 24] , and rheumatoid arthritis [25] . Morphine tolerance shares a similar pathobiological mechanism with chronic pain. However, there are no studies that have examined the possible effects of these B vitamins in experimental animals with respect to the development of antinociceptive tolerance to morphine. It has also been reported that chronic exposure to thiamine, pyridoxine, and cyanocobalamin protects neurons from glutamate or NMDA-mediated excitotoxicity in vitro [26, 27] . In addition, galactooligosaccharides (GOS), which could significantly improve the absorption and synthesis of B vitamins, orally could suppress the activation of microglia and regulate several inflammatory-related factors in mice [28] . Therefore, given the importance of the NMDA receptor and activated microglia in the development of morphine tolerance, we hypothesized that these B vitamins (thiamine, pyridoxine, and cyanocobalamin) may interfere with morphine-induced NMDA receptor and microglia activation and inhibit morphine tolerance development.
In our study, we report for the first time that B vitamins can significantly potentiate acute morphine antinociception and attenuate the development of antinociceptive tolerance to morphine administered chronically. Moreover, chronic morphine treatment can increase the activation of NMDA receptor and microglia. Our results demonstrated that B vitamins decreased the phosphorylation (activation) of the NR1 subunit of the NMDA receptor and attenuated the activation of microglia following chronic morphine administration.
Methods

Ethics Statement
All procedures were strictly performed in accordance with the regulations of the ethics committee of the International Association for the Study of Pain and   the Guide for the Care and Use of Laboratory Animals  (The Ministry of Science and Technology of China,  2006 ). All animal experiments were approved by the Nanjing Medical University Animal Care and Use Committee and were designed to minimize suffering and the number of animals used.
Animals, Anesthesia, and Intrathecal Administration
Adult male ICR mice (18-22 g wt; the Experimental Animal Center at Nanjing Medical University, Jiangsu province, China) were used in this study. Animals were housed five to six per cage under pathogen-free conditions with soft bedding under controlled temperature (22 6 2 C) and photoperiods (12:12-hour light-dark cycle). Mice were allowed to acclimate to these conditions for at least two days before inclusion in experiments. For each group of experiments, mice were matched by age and body weight. Experimenters who performed behavioral tests, drug administration, and/or preparing the spinal cord tissues for Western blot analysis and immunohistochemistry were blinded. Mice were anesthetized with pentobarbital (50 mg/kg, i.p.) for preparing the spinal cord tissue for Western blotting and immunobiochemistry. Morphine was dissolved in saline and then injected intrathecally (i.t. 10 mg/10 ml/mouse) under brief inhalational anesthesia by means of lumbar puncture at the intervertebral space of L4-5 and L5-6 for multiple injections using a stainless steel needle (30 gauge) attached to a 25 lL Hamilton syringe. A total of eight mice were included in each group.
Materials
Morphine was purchased from Shenyang First pharmaceutical factory, Northeast Pharmaceutical Group Company (China). Thiamine, pyridoxine, and cyanocobalamin were purchased from Sigma (USA).
Western Blot
To investigate possible temporal changes in the expression of GFAP, IBA-1, GAPDH, and phosphorylated levels of ERK, JNK, p38/MAPK, NR1, and PKC, whole cell protein extract lysates were analyzed as described before [29] [30] [31] . The lanes were representative of individual animals. In brief, samples (spinal cord segments at L4-L6) were collected and washed with ice-cold phosphate buffered saline (PBS) before being lysed in RIPA. Then whole sample lysates were collected for protein expression assay with the primary antibodies (GAPDH, 1:1000 from Sigma; p-p38(Tyr182), 1:800, Abcam; IBA-1, 1:1000, Wako Pure Chemical Industries; p-NR1(Ser896), p-JNK (Thr183/Tyr185), p-ERK (T202)/(Y204), p-PKC, 1:1000, Cell Signaling Technology). Secondary antibodies were from Chemicon. Data were analyzed with the Molecular Imager (Gel DocTM XR, 170-8170) and the associated software Quantity One-4.6.5 (Bio-Rad Laboratories).
Immunohistochemistry
Under deep anesthesia, mice and rats were transcardially perfused with PBS, followed by 4% paraformaldehyde. L4 and/or L5 lumbar segments were dissected out and postfixed in the same fixative. The embedded blocks were sectioned as 30 lm thick. Sections from each group (five mice in each group) were incubated with rabbit anti-IBA-1 polyclonal antibody (1:100, Abcam) or anti-GFAP antibody (1:200, Millipore). Then the free-floating sections were washed with PBS and incubated with the secondary antibody for two hours. After washing three times with PBS, the samples were studied under a confocal microscope (Leica TCS SP2) for morphologic details of the immunofluorescence staining. Images were randomly coded and transferred to a computer for further analysis. A total of eight mice were included in each group. *P < 0.05 and **P < 0.01 indicate significant difference compared with morphinealone group.
Effect of Vitamin B Complex on Development of Antinociceptive Tolerance to Morphine
To assess possible effects of the vitamin B complex on the extent of development of morphine tolerance, mice received morphine by s.c. injection (10 mg/kg) once daily for seven days, and antinociception was measured at 30 minutes after each injection [29] [30] [31] [32] . A total of eight mice were included in each group. *P < 0.05 and **P < 0.01 indicate significant difference compared with morphine-alone group. † P < 0.05 and † † P < 0.01 indicate significant differences compared with control. AUC ¼ area under the curve; MPE ¼ maximal possible effect; VPC ¼ vitamin B complex. curve (AUC) for 0 to 180 minutes after morphine injection to indicate degree of antinociception as described before [33] .
Tail Flick Test
The hot water tail flick test was performed by placing the distal third of the tail in a water bath maintained at 48 C to investigate the effect of vitamin B complex on pain threshold in naïve mice or 52 C to investigate the effect of vitamin B complex on the development of chronic morphine tolerance. The test was performed by gently holding the mouse in a terry cloth towel and immersing between 2 and 3 cm from the tip of the tail into warm water. The latency until tail withdrawal from the bath was determined. In the water bath maintained at 52 C, if mice did not show tail withdrawal response in 10 seconds, we ceased the experiment, and 10 seconds was used as cutoff to avoid tissue damage. Data were calculated as percentage of maximal possible effect (% MPE), which was calculated by the following formula: 100% Â [(drug response time- 
Statistical Analysis
SPSS Rel 15 was used to conduct all the statistical analyses. Alteration of expression of the proteins detected and the behavioral responses to morphine treatment were tested with one-way analysis of variance (ANOVA), and the differences in latency over time among groups were tested with two-way ANOVA, respectively, followed by Bonferroni post hoc tests. The mean fluorescent pixels of IBA-1 were measured by Image Pro Plus 6.0. Results are expressed as mean 6 s.e.m. of three independent experiments in triplicate. Results described as significant are based on a criterion of P values of less than 0.05.
Results
Vitamin B Complex Potentiates Acute Morphine Antinociception and Attenuates Antinociceptive Tolerance to Subcutaneous Morphine Administered Chronically
Antinociceptive response induced by acute morphine progressively declined at 90 minutes, being almost completely abolished at 150-180 minutes in mice. The MPE observed in acutely morphine-treated mice at 150 and 180 minutes were 30.8% and 25.2%, respectively ( Figure 1A) . However, mice pretreated with vitamin B complex (intraperitoneal administration, 15 minutes Spinal cord samples were collected and analyzed 30 minutes after the last morphine administration. A total of four mice were included in each group. *P < 0.05 and **P < 0.01 indicate significant difference. † P < 0.05 and † † P < 0.01 indicate significant differences compared with control. VPC ¼ vitamin B complex. before 10 mg/kg morphine subcutaneous injection) still showed the antinociceptive effect at 150-180 minutes ( Figure 1, A and B) ; levels in mice treated with a high dose of vitamin B complex (VBC-H) were 55.5% at 150 minutes and 45.4% at 180 minutes, respectively.
We further investigated the impact of vitamin B complex on the development of chronic morphine tolerance. Thermal tail flick test was conducted at 30 minutes after morphine to get thermal latency. There was a significant decline in antinociception after treatment with chronic morphine in mice, such that the % MPE observed at 30 minutes postdosing on day 7 was 19.8% MPE ( Figure 1C ), whereas levels in mice treated with vitamin B complex (VBC-L, VBC-M, or VBC-H) simultaneously were 35.7%, 48.2%, and 39.1%, respectively ( Figure 1, C and D) .
Vitamin B Complex Potentiates the Acute Intrathecal Morphine Antinociception and Suppresses Intrathecal Morphine Chronic Tolerance
Apart from systemic administration, the most common dosing route for morphine is intrathecal administration. Therefore, we investigated the impact of vitamin B complex on acute intrathecal morphine antinociception and on the decreased antinociception induced by repeated intrathecal administration of morphine. Co-administration of morphine (10 lg/10 ll, i.t.) and vitamin B complex (VBC-H, VBC-M, and VBC-L, i.p.) significantly potentiated acute Spinal cord samples were collected and analyzed 30 minutes after the last morphine administration. B) Vitamin B complex inhibited the increase in p38 MAPK phosphorylation induced by chronic morphine treatment. Representative Western blot bands and a data summary for p-p38 are shown. A total of four mice were included in each group. *P < 0.05 and **P < 0.01 indicate significant difference. † P < 0.05 and † P < 0.01 indicate significant differences compared with control. VPC ¼ vitamin B complex. morphine antinociception (Figure 2, A and B) . The MPE observed in acutely morphine-treated mice at 180 minutes was 15.0% ( Figure 2A) . However, mice pretreated with vitamin B complex (intraperitoneal administration, 15 minutes before 10 lg/10 ll morphine intrathecal injection) still showed the antinociceptive effect at 180 minutes ( Figure  2, A and B) ; the level in mice treated with a high dose of vitamin B complex (VBC-H) was 58.8% at 180 minutes. Morphine (10 lg, i.t.) was administered once daily for seven days. The thermal tail flick test was conducted at 30 minutes after morphine to get thermal latency. Our data suggested that vitamin B complex could effectively attenuate the tolerance developed by repeated intrathecal injection of morphine (Figure 2, C and D) .
Vitamin B Complex Suppresses Phosphorylation Level of NMDAR-NR1 Subunit and PKC Following Chronic Morphine Treatment in the Spinal Cord
Increasing evidence suggests that activation of the NMDA receptor in the spinal cord plays a critical role in the development of morphine tolerance [34] [35] [36] [37] . Moreover, PKC has been shown to modulate NMDA receptor activation and contribute to morphine tolerance [34, 36, 38] . In the present study, we demonstrated that morphine exposure increased the extent of phosphorylation of the NMDA-NR1 subunit (p-NR1), which has a well-established role in opiate-related neural plasticity, as well as the phosphorylation level of PKC (p-PKC) in the mouse spinal cord, and the repetitive administration of vitamin B complex (i.p., 15 minutes before the injection of morphine each day) suppressed such increased phosphorylation of NR1 and PKC induced by repeated administration of morphine (Figure 3, A and B) .
Vitamin B Complex Inhibits Morphine-Induced
Microglia Activation, as well as the Increase in p38/MAPK Phosphorylation-Induced IL-1b Progress in tolerance research points to an important role of microglia in the development of morphine tolerance. Accumulating evidence demonstrates that spinal cord microglia are strongly activated after chronic opioid exposure, and inhibition of spinal cord microglia has been shown to attenuate morphine-induced antinociceptive tolerance. Consistently with these reports and our previous behavioral results, Western blotting and immunofluorescence data demonstrated that mice with repeated intrathecal morphine exposure showed significant microglia activation, manifested as robust upregulation of the microglial marker, IBA-1, in the spinal cord (Figures 4A and 6A) . Treatment with vitamin B complex could significantly reverse these pathological changes ( Figure 4A and 6A) . It has been demonstrated that activation of microglia could increase the expression of IL-1b, which could bind with their corresponding receptors in neurons and then activate the NMDA receptor [39] . Therefore, we further examined the effect of vitamin B complex on IL-1b. Western blot analysis revealed that the vitamin B complex could significantly reduce the increase of the proinflammatory cytokine IL-1b in the spinal cord ( Figure 4A ). Activated microglia not only exhibit increased expression of the microglial marker IBA1, but also display elevated phosphorylation of p38 mitogen-activated protein kinase. Evidence demonstrates that systemically or intrathecally repeated morphine induces upregulation of phosphorylation of p38 [14, [40] [41] [42] . We further examined the impact of vitamin B complex on the phosphorylation of p38/MAPK in a chronic morphine tolerance model. Western blot analysis data showed that the vitamin B complex could significantly reduce the upregulation of p38/MAPK phosphorylation (p-P38) induced by morphine exposure in the spinal cord ( Figure 4B ).
Taking into account that, in addition to microglia, astrocytes can also release IL-1b, we further examined the effect of vitamin B complex on the astrocyte. Western blot analysis revealed that vitamin B complex could neither change the increase of GFAP, which is the marker of astrocyte, nor affect the increased phosphorylation of JNK in the spinal cord, another member of mitogenactivated protein kinases (MAPK), which is known to selectively express in spinal cord astrocytes [43, 44] (Figures 5 and 6B ). Mean fluorescence pixels ‡ * ** Figure 6 Confocal images of imunostaining and immunofluorescence analysis of effects of vitamin B complex on spinal microglia marker IBA1 (A) and astrocyte marker GFAP (B) associated with chronic morphine treatment (four to five images per animal). Original magnification, Â400. A total of five mice were included in each group. *P < 0.05 and **P < 0.01 indicate significant difference. † P < 0.05 and † † P < 0.01 indicate significant differences compared with control. VPC ¼ vitamin B complex.
Discussion
The present study investigated effects of B vitamins on acute morphine antinociception and chronic morphine tolerance, as well as the upregulation of p-NR1, p-PKC, p-P38/MAPK, IL-1b, and activation of microglia in the lumbar spinal cord after chronic morphine treatment, supporting the promise of B vitamins for suppressing morphine tolerance to increase the clinical analgesic efficacy of opioids. Representative Western blot bands and a data summary (N ¼ 4) for IBA-1 and GFAP are shown. *P < 0.05 and **P < 0.01 indicate significant difference.
Since the initial report in 1991 of a link between NMDA and morphine tolerance [45] , evidence rapidly accumulated that the NMDA receptor is an important mediator of morphine tolerance and that an NMDA receptor antagonist can not only attenuate the development of tolerance to the analgesic effect of morphine, but also suppress glial pro-inflammatory cytokine expression in morphine-tolerant rats [37, [45] [46] [47] [48] [49] [50] . NMDA receptor activation can reduce the analgesic potency of morphine and accelerate the development of opioid tolerance [51, 52] . In the nervous system, the interaction of morphine with the G protein-coupled Mu-opioid receptor (MOR) provokes the development of analgesic tolerance. Morphine desensitizes the MOR via a process that requires persistent activation of the NMDA receptor. The activated MOR are perceived by the associated NMDA receptor, which in turn exerts a negative feedback effect on MOR signaling. MOR-and NMDA receptor-mediated signals work together in a sequential and interconnected manner to induce MOR desensitization ultimately [53] . Meanwhile, the administration of morphine provokes phosphorylation of the NMDA receptor, increases intracellular Ca 2þ release, and then potentiates PKC to disrupt the complex of morphine and MOR, which also contributes to MOR desensitization [54] . Opioid treatment can cause translocation of PKC to the plasma membrane [38, 55] and PKC activation [56] . Increased PKC activity could potentiate presynaptic NMDA receptor function by reducing the Mg 2þ block of the NMDA receptor and promoting NMDA receptor trafficking to the plasma membrane [57, 58] . Morphineinduced analgesic tolerance is prevented and even efficiently rescued by inhibition of PKC [36, 38, 59] . In agreement with these reports, our results demonstrate that chronic treatment with B vitamins can prevent the phosphorylation of NR1 and PKC induced by chronic morphine exposure and attenuate morphine tolerance development.
Moreover, it is reported that the NMDA receptor can activate glia and induce the release of proinflamatory cytokines [60] [61] [62] [63] . Mounting compelling evidence indicates that spinal microglia play a crucial role in the pathogenesis of morphine tolerance [41, 64, 65] . Spinal cord microglia are strongly activated after chronic opioid exposure. Increasing evidence suggests that, under this condition, activated microglia not only exhibit increased expression of the microglial markers CD11b and IBA1, but also display elevated phosphorylation of p38 MAPK. Minocycline (microglia inhibitor) and SB203580 (p38 inhibitor) have been shown to significantly attenuate morphine-induced pro-inflammatory cytokine synthesis and to inhibit morphine tolerance [41, 66] . Activation of p38 in spinal microglia results in increased synthesis and release of the proinflammatory cytokine IL-1b. It is now clear from recent studies that chronic morphine activates microglial p38 MAP kinase [67] and stimulates the production of spinal proinflammatory cytokines [14, 40, 68] , both of which are involved in the development of morphine tolerance [67, 69] . Moreover, IL-1b can increase phosphorylation of the NMDA receptor and enhance NMDA currents [70, 71] , contributing to the hyperactivity of dorsal horn neurons, leading to central sensitization and a reduction in morphine analgesic efficacy. Morphine tolerance was slowed by knockout of IL-1 signaling [72] . Our data showed that B vitamins notably inhibited microglia activation, suppressing the upregulated IBA-1 expression, p38 MAPK phosphorylation, and IL-1b in the dorsal horn of the lumbar spinal cord.
In addition, B vitamins at a high dose showed no notable effects on pain threshold, as well as on the expression of IBA-1 and phosphorylation of p38, while a dosing regimen that significantly attenuated the development of morphine tolerance. Concomitant treatment with B vitamins and morphine may lead to more sustained pain relief in the clinical setting than treatment using morphine alone. However, this remains to be investigated in future clinical studies.
Conclusions
These results add a possible new role for B vitamins in potentiating morphine antinociception and reducing morphine tolerance, in addition to the analgesic effects in different forms of painful conditions.
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